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Edited by Noboru MizushimaAbstract The cyclic AMP response element-binding protein
(CREB) is involved in the development and function of the ner-
vous system. Here, we ﬁnd that CREB decreases the protein level
of Regulator of Calcineurin Activity 1 (RCAN1/DSCR1/
MCIP1), which is overexpressed in the brain of Down Syndrome
(DS) patients. Decrease of RCAN1 by CREB was blocked by
proteasome inhibitors, indicating that this decrease is mediated
by the ubiquitin-proteasome pathway. Furthermore, we found
that the ability of CREB to activate the degradation of RCAN1
depends on its transcriptional activation. Consistently, CREB-
enhanced the ubiquitination and turnover rate of RCAN1. Our
results reveal a new regulatory role for CREB in DS pathology
through the proteasomal degradation of RCAN1.
 2008 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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DS1. Introduction
Down Syndrome (DS) is the leading genetic disease caused
by trisomy of chromosome 21 [1]. The Regulator of Calcineu-
rin Activity 1 (RCAN1, also called as DSCR1, Adapt78, and
MCIP1) gene is located in the DS region of chromosome 21,
and it is critical for the phenotype of DS and highly expressed
in brains of DS and Alzheimer Disease (AD) patients [2]. A re-
cent study found that RCAN1 physically and functionally
associates with calcineurin, a phosphatase critical for learning
and memory by regulating the phosphorylation/dephosphoryl-
ation of transcription factors [3]. Moreover, loss-of-function
and overexpression mutants of Nebula, the Drosophila homo-
log of human RCAN1, exhibited severe learning defects due to
disregulation of the calcineurin-mediated signaling pathway
[4].
Cyclic AMP response element-binding protein (CREB) is
best known for acting as a transcriptional regulator in the
development and function of neurons [5]. In the brain, it is in-
volved in learning, memory, and synaptic transmission, as well
as in neuronal survival, diﬀerentiation, and axonal growthAbbreviations: CREB, cyclic AMP response element-binding protein;
RCAN1, Regulator of Calcineurin Activity 1; DS, Down Syndrome
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doi:10.1016/j.febslet.2008.04.059[5,6]. CREB aﬀects the function of the nervous system by alter-
ing the expression of a variety of genes through interactions
with cyclic AMP/Ca2+ response elements (CRE) within their
promoter sequences [5,7]. Recent studies using chromatin
immunoprecipitation and DNA microarray techniques identi-
ﬁed several CREB-regulated genes [8,9], demonstrating that
CREB regulates distinct subsets of genes in diﬀerent circum-
stances. Multiple ﬁndings have suggested that CREB-mediated
gene transcription is critical in maintaining a homeostatic cel-
lular environment under pathological conditions. For example,
CREB-mediated gene expression is necessary for the induction
of ischemic tolerance [10]. Likewise, CREB-overexpressing
PC12 cells have decreased susceptibility to apoptosis [11],
and augmentation of CREB-dependent transcriptional activa-
tion substantially suppresses polyglutamine-induced cytotoxic-
ity [12]. However, the implication of CREB in DS pathology,
which is based on altered gene dosage of chromosome 21 pro-
teins, has yet to be addressed.
To examine the function of CREB in DS pathology, we
expressed CREB and RCAN1 in neuronal cells, and identiﬁed
an unexpected role for CREB in decreasing RCAN1 stability.
We observed that the decrease in RCAN1 stability by CREB
occurs as a result of ubiquitination with subsequent degrada-
tion in the proteasome. Furthermore, we found that the ability
of CREB to regulate the degradation of RCAN1 depends on
its transcriptional activation. Our data reveal a new regulatory
mechanism that connects CREB signaling with DS pathology
through RCAN1 degradation.2. Materials and methods
2.1. Materials and expression vectors
Anti-HA, anti-Myc, and anti-GFP antibodies were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA). Anti-Flag antibody was
purchased from Sigma–Aldrich (St. Louis, MO). MG132, Lactacy-
stein, and ALLN were purchased from Calbiochem (Sandiego, CA).
The expression vector for HA-RCAN1 was kindly provided by S. de
la Luna. Expression vectors for a wild-type and a deletion construct
of GFP-RCAN1 were gifts from B.A. Rothermel. Point mutants in
RCAN1 such as S108A, 112A, and S108/112A were generated by
polymerase chain reaction (PCR). The dominant-negative mutants of
E2 ubiquitin ligases (His-UbcH5a.DN, His-UbcH5b.DN, His-
UbcH5c.DN, His-UbcE20K.DN) were a gift from K. Iwai. Expression
vectors for pCG-CREB and CREB (S133A) were a gift from K. Saeki.
A PCR-based procedure with pCG-CREB as a template was used to
generate Flag-CREB. A-CREB was a gift from D.D. Ginty.
2.2. Cell culture
Human neuronal SH-SY5Y cells were maintained in DMEM sup-
plemented with 10% FBS, penicillin, and streptomycin. Cells were
transfected with expression vectors by the LipofectAmine method
(Invitrogen). After 24 h, cells were lysed in lysis buﬀer [20 mM Tris–blished by Elsevier B.V. All rights reserved.
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Glycerol, 1 mM Na3VO4, 1 lg/ml leupeptin, 1 lg/ml aprotinin,
10 mM NaF, and 0.2 mM phenylmethylsulfonyl ﬂuoride].
2.3. Immunoprecipitation and immunoblotting
Cell lysates were subjected to immunoprecipitation with anti-HA
antibody for 2 h, followed by adsorption to sepharose-coupled protein
G for 1 h. For immunoblot analysis, total cell lysates were separated
by 10% SDS–PAGE, and proteins were transferred to nitrocellulose
membranes. The membranes were blocked in TBST buﬀer [20 mM
Tris–Cl (pH 7.6), 137 mM NaCl, 0.05% Tween 20, and 3% non-fat
dried milk] for 30 min then incubated overnight at 4 C with the appro-
priate antibodies.
2.4. Pulse-chase analysis
For experiments examining the metabolic stability of RCAN1, cells
were preincubated for 1 h in Met/Cys-free DMEM and labeled for
10 min with 100 lCi/ml [35S]-Met/Cys in Met/Cys-free DMEM. The
cells were chased for the indicated time periods and the cell lysates
were subjected to immunoprecipitation. The immunoprecipitates were
resolved by SDS–PAGE, visualized by phosphoimager, and quantiﬁed.
2.5. RT-PCR
RNA preparation, reverse transcription, and PCR were performed
as described previously [13]. The primers were: RCAN1 forward, 5 0-
GAGGAGGTGGACCTGCAGGACCTG-3 0; RCAN1 reverse, 5 0-
TCAGCTGAGGTGGATCGGCGTGTAC-3 0; GAPDH forward, 5 0-
ACCACAGTCCATGCCATCAC-3 0; GAPDH reverse, 5 0-TCCAC-
CACCCTGTTGCTGTA-3 0.3. Results and discussion
3.1. CREB decreases the steady-state protein expression of
RCAN1
To begin our investigation of the function of CREB in DS
pathology, we expressed CREB together with RCAN1 in neu-
ronal SH-SY5Y cells (Fig. 1A). Interestingly, we observed that
CREB decreased the steady-state level of RCAN1 in a dose-
dependent manner. To determine if the signiﬁcant reductionHA-RCAN1
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Fig. 1. Decreased protein expression of RCAN1 by CREB. (A) SH-
SY5Y cells were transfected with HA-RCAN1 and increasing amounts
of Flag-CREB. After 24 h, the expression of HA-RCAN1, Flag-
CREB, and b-actin was assessed by immunoblotting with the indicated
antibodies. (B) SH-SY5Y cells were transfected with HA-RCAN1
alone or together with Flag-CREB and expressed for 24 h. mRNA
levels of RCAN1 and GAPDH in each sample were measured by RT-
PCR. (C) SH-SY5Y cells were treated with or without forskolin for 1 h
and mRNA levels of RCAN1 and GAPDH in each sample were
measured by RT-PCR.in RCAN1 expression by CREB is due to a decrease in tran-
scription, we performed RT-PCR. As shown in Fig. 1B, the le-
vel of RCAN1 mRNA was not altered by CREB, suggesting
that CREB does not aﬀect the transcription of RCAN1. We
next determined whether the activation of endogenous CREB
by forskolin, an intracellular adenylate cyclase activator, can
aﬀect the mRNA level of endogenous RCAN1. As shown in
Fig. 1C, activation of endogenous CREB had no eﬀect on
the mRNA level of endogenous RCAN1 in SH-SY5Y cells.
Together, these results suggest that CREB decreases the
expression of RCAN1 by increasing protein degradation
rather than decreasing protein synthesis (Fig. 1C).3.2. CREB activates the degradation of RCAN1 through the
ubiquitin-proteasome pathway
Previously, it has been reported that RCAN1 protein is reg-
ulated by ubiquitin-proteasome pathway [14,15]. We next
determined whether the CREB-induced decrease in RCAN1
expression might occur through the ubiquitin-proteasome
pathway. Consistent with previous report [15], incubation of
cells in the presence of the well-known proteasome inhibitor
MG132 clearly increased the amount of the RCAN1 (Fig.
2A). Interestingly, blocking of proteasome by MG132 rescued
the decreased protein expression of RCAN1 by CREB to the
control level (Fig. 2A). Other proteasome inhibitors such as
lactacystin and ALLN, also blocked decreased RCAN1
expression by CREB, conﬁrming that the CREB-induced de-
creased expression of RCAN1 is due to protein degradation
by the proteasome (Fig. 2B).
To verify that RCAN1 is targeted for degradation through
the ubiquitin-proteasome pathway, various dominant-negative
E2 ubiquitin-conjugating enzymes were tested for their ability
to block the ubiquitin-dependent degradation of RCAN1 by
CREB. These E2 ubiquitin-conjugating mutant enzymes con-
tain catalytic site mutations and have been shown to behave
in a dominant-negative manner [16,17]. We observed that
expression of the dominant-negative mutants UbcH5a,
UbcH5b, and UbcH5c caused a signiﬁcant inhibition in the
ability of CREB to decrease RCAN1 protein in the steady-
state (Fig. 2C). This eﬀect was speciﬁc to the UbcH5 family be-
cause transfection of the dominant-negative mutant UbcE20K
exhibited less of any eﬀect on the expression level of RCAN1
by CREB. These results conﬁrm that the CREB-induced de-
crease in RCAN1 protein is mediated by the ubiquitin-prote-
asomal degradation pathway.3.3. CREB degrades the C-terminal domain of RCAN1
To determine which domains of RCAN1 are speciﬁcally tar-
geted by CREB for degradation, we expressed several deletion
constructs encoding RCAN1 fragments fused to GFP. As
shown in Fig. 3A, we found that CREB decreased the expres-
sion of RCAN1 peptide fragments containing amino acids 30–
197 and 90–197 as well as full length RCAN1. However,
CREB did not aﬀect the expression of RCAN1 fragments con-
taining the N-terminal 90 amino acids, suggesting that the
RCAN1 domain critical for degradation by CREB is con-
tained within amino acid residues 90–197. To characterize fur-
ther whether the phosphorylation state of RCAN1 in the 90–
197 domain is required for degradation by CREB, we gener-
ated Ser mutants, S108A and S112A as well as the double mu-
tant S108/112A, which have previously been shown to be
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Fig. 2. Ubiquitin-dependent degradation of RCAN1 by CREB. (A
and B) SH-SY5Y cells were transfected with HA-RCAN1 alone or
together with Flag-CREB and expressed for 24 h. Cells were treated
with or without the indicated inhibitor [MG132 (10 lM), Lactacystin
(5 lM), or ALLN (50 lM)] for 6 h before lysis and then the expression
of HA-RCAN1 and Flag-CREB was assessed by immunoblotting with
indicated antibodies. (C) SH-SY5Y cells were transfected with HA-
RCAN1 alone or together with Flag-CREB and the indicated
dominant-negative mutants of E2-ligases tagged with His. Cell lysates
were immunoblotted with the indicated antibodies.
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Fig. 3. Degradation of C-terminal domain of RCAN1 by CREB. SH-
SY5Y cells were transfected with indicated combinations of deletion
constructs of GFP-RCAN1, point mutants of HA-RCAN1, and Flag-
CREB. After 24 h, the expression of GFP-RCAN1, HA-RCAN1, and
Flag-CREB was assessed by immunoblotting with indicated antibod-
ies.
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Fig. 4. Degradation of RCAN1 by transcriptional activation of
CREB. SH-SY5Y cells were transfected with indicated combinations
of HA-RCAN1, Flag-CREB (WT), Flag-CREB (S133A), and Flag-A-
CREB. After 24 h, the expression of HA-RCAN1, and Flag-CREB
was assessed by immunoblotting with indicated antibodies.
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and ERK [18,19]. As shown in Fig. 3B, CREB decreased the
expression of these mutants to the same extent as that of the
wild-type protein, indicating that these sites are not speciﬁcally
targeted for degradation by CREB.
3.4. Transcriptional activation of CREB mediates the
degradation of RCAN1
We next explored whether the ability of CREB to activate
the degradation of RCAN1 is due to its transcriptional activa-
tion. First, we expressed CREB mutated at Ser133 [20], a res-
idue which is critical for the transcriptional activation of
CREB, together with RCAN1 (Fig. 4A). As shown in Fig.
4A, we did not detect any signiﬁcant decrease in the expression
of RCAN1 by S133A, indicating that the degradation ofRCAN1 is mediated by transcriptional activation of CREB.
To further demonstrate that CREB requires transcriptional
activation for the degradation of RCAN1, we expressed
RCAN1 with a dominant-negative inhibitor of CREB (A-
CREB) [21]. Consistent with the previous result, the expression
level of RCAN1 was unchanged by the expression of A-CREB
(Fig. 4B). Furthermore, coexpression of CREB with domi-
nant-negative A-CREB signiﬁcantly inhibited the degradation
of RCAN1 by CREB, conﬁrming that the ability of CREB to
degrade RCAN1 is mediated by its transcriptional activation.
3.5. Transcriptional activation of CREB enhances the turnover
rate and ubiquitination of RCAN1
To determine whether the decreased level of RCAN1 by
CREB is due to enhanced turnover of RCAN1 protein, we
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Fig. 5. Increased turnover rate and ubiquitination of RCAN1 by
transcriptional activation of CREB. (A and B) SH-SY5Y cells
transfected with indicated combinations of HA-RCAN1, Flag-CREB,
and Flag-A-CREB were pulse labeled with [35S]-Met/Cys and chased
for the indicated times. Cell lysates were immunoprecipitated with
anti-HA antibody, and [35S]-labeled HA-RCAN1 proteins were
visualized by phosphoimager (A) and quantiﬁed (B). Labeled proteins
are plotted at each time point as a percentage of the amounts present at
time zero (B). (C) SH-SY5Y cells were transfected with indicated
combinations of Myc-RCAN1, HA-Ubiquitin (Ub), Flag-CREB, and
Flag-A-CREB. Before lysis, cells were treated with MG132 (10 lM)
for 6 h. Cell lysates were immunoprecipitated (IP) with anti-HA
antibody and immunoblotted with anti-Myc antibody.
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absence of CREB by pulse-chase analysis. As shown in Fig. 5A
and B, coexpression of CREB signiﬁcantly enhanced the turn-
over rate of RCAN1 protein. However, dominant-negativeCREB (A-CREB) had no signiﬁcant eﬀect on RCAN1 turn-
over, indicating that CREB enhances the turnover rate of
RCAN1 through its transcriptional activation (Fig. 5A and
B). We also tested whether CREB enhances the ubiquitination
of RCAN1 through its transcriptional activation (Fig. 5C). As
shown in Fig. 5C, the ubiquitination of RCAN1 was signiﬁ-
cantly increased by CREB coexpression. Furthermore, domi-
nant-negative CREB (A-CREB) did not enhance the
ubiquitination of RCAN1, conﬁrming that CREB-enhanced
ubiquitination of RCAN1 is dependent on its transcriptional
activation (Fig. 5C).
In summary, our ﬁndings provide the ﬁrst evidence that
transcriptional activation of CREB facilitates the ubiquitin-
dependent degradation of RCAN1 through the proteasome.
We speculate that the ability of CREB to regulate the stability
of RCAN1 results from activation of ubiquitin enzymatic cas-
cade reactions including E1, E2, and E3 [22]. Recently, it has
been reported that the SCFCDC4 E3 ubiquitin ligase complex
triggers the degradation of yeast Rcn1, a homologue of
RCAN1 [23]. Therefore, it is possible that RCAN1 is a target
of this enzyme or another E3 enzyme. There have been many
reports suggesting that CREB activates E3 ubiquitin ligase
[24–26]. For example, BRCA1 E3 ubiquitin ligase has a CRE
site in its proximal promoter [24] and can associate with the
CREB binding domain of p300/CBP [25]. In addition,
ATF1, a member of the CREB family, can physically and
functionally interact with the RING-ﬁnger motif of E3 ubiqui-
tin ligase [26]. It remains to be elucidated whether (and how)
CREB modulates the expression of these E3 enzymes directly
or indirectly by activating a regulatory protein that is involved
in the degradation of RCAN1. We speculate that overexpres-
sion of RCAN1 might activate CREB by increasing its CRE-
binding activity. We are currently examining this issue to see
if RCAN1 activate CRE-containing gene transcriptional activ-
ity. Based on these observations, it is tempting to speculate
that CREB may function to modulate the proper level of
RCAN1, which could consequently lessen the abnormally
accumulated RCAN1-linked defects in DS patients.
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